Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (283 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-08-25. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastasesunresectablecoronaryfailureprior to
  Phrases that lowered it: investigatoriupsoriasisevaluate thehcv
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Minimum age: 20 (lowers risk) · Who can join
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 5 (raises risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 20.0% (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 89.5% (raises risk) · Drug's FDA history
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports before start: 315704 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 35161 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC NCT06238752 · started 2021 · scored riskier than 49% of active trials completed
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) NCT03281369 · started 2017 · scored riskier than 48% of active trials terminated
• Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma NCT07529613 · started 2023 · scored riskier than 57% of active trials completed
• Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma NCT02862535 · started 2016 · scored riskier than 30% of active trials terminated
• Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer NCT01388790 · started 2011 · scored riskier than 46% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.